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Endovascular Thrombectomy in Patients with Large Core Ischemic Stroke: A CostEffectiveness Analysis from the SELECT Study

Abstract:
Background: Whether endovascular thrombectomy (EVT) is cost-effective in large ischemic
core infarcts is unknown.
Methods: In the prospective multicenter cohort study of imaging selection study (SELECT),
large core was defined as CT ASPECTS < 6 or CTP ischemic core volume (rCBF<30%) ≥ 50 cc.
A Markov model estimated costs, quality-adjusted life years (QALYs) and the incremental costeffectiveness ratio (ICER) of EVT compared to medical management (MM) over life time. The
lower and upper willingness to pay (WTP) per QALY were set at $50,000 and $100,000 and the
net monetary benefit (NMB) for EVT were calculated. Probabilistic sensitivity analysis (PSA)
and cost-effectiveness acceptability curves (CEAC) were assessed for EVT in SELECT and
other pivotal EVT trials.
Results: From a prospective cohort trial of 361 patients, 105 had large core on CT or CTP (EVT
62, MM 43). 19 (31%) EVT patients achieved mRS 0-2 vs 6 (14%) MM patients (aOR: 3.27,
95% CI: 1.11-9.62; P = .03) with a shift towards better mRS (adj cOR: 2.12, 95% CI: 1.05-4.31,
P = .04). Over the projected lifetime of stroke patients presenting with large ischemic core, EVT
was associated with incremental costs of $33,094 and a gain of 1.34 QALYs per patient,
resulting in ICER of $24,665 per QALY. EVT has a higher NMB compared to MM at the lower
(EVT: -$42,747 vs MM: -$76,740) and upper (EVT: $155,041 vs MM: $57,134) thresholds of
willingness to pay. The PSA confirmed the results and the CEAC showed 77% and 92% cost-
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effectiveness probability of EVT at the WTP of $100,000, respectively. EVT was associated with
an increment of $28,962 in societal costs. The Pivotal EVT trials (HERMES, DAWN and
DEFUSE 3) were dominant in a sensitivity analysis at the same inputs, with societal cost savings
of $38,072, $86,358 and $22,837, respectively.
Conclusion: EVT may result in better outcomes in large core patients with higher QALYs,
NMB and high cost-effectiveness acceptability rates based on current WTP thresholds.
Clinical Trial Registration: http://www.clinicaltrials.gov. Unique identifier: NCT02446587
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Introduction
Stroke is a global health problem, with more than 13 million new strokes and 5.5 million deaths
every year1. In the USA, every year 795,000 individuals suffer from new or recurrent stroke,
resulting in 140,000 deaths2. Stroke is also the leading cause of serious long-term disability,
resulting in 116.5 million quality-adjusted life year (QALY) lost1 worldwide every year.
Moreover, it is an expensive disease to treat and manage with annual direct costs of $28 billion
and indirect costs of $17.5 billion on the US economy, with a projected increase in direct costs to
$94.3 billion by year 20352. Effective stroke treatments that improve clinical outcomes and
reduce disability may help reduce the economic burden of stroke in society and in our health care
systems by reducing direct and indirect costs.

Endovascular thrombectomy (EVT) has been established as a transformative treatment for
ischemic stroke patients with large vessel occlusion; safety and efficacy have been well
documented in patients with small ischemic core infarcts, both in early3–7 and late8,9 time
windows. While randomized trials for efficacy and safety of EVT in patients with large ischemic
stroke are ongoing10–13, potential evidence of EVT efficacy and safety in these patients was
recently presented from a large, multicenter, prospective cohort data14. With prevalence of large
core strokes estimated to be as high as ~30%14, these patients are frequently encountered in daily
practice. Treating physicians have several considerations while determining the treatment
approaches, such as the poor natural history in patients treated with medical management only as
compared to the lower likelihood of functional independence and the potential safety concerns
with EVT. One of the considerations for the healthcare systems and for society is whether
treatment with endovascular thrombectomy is cost-effective. While cost-effectiveness of EVT in
4

patients with small ischemic core has been assessed and deemed favorable15–21, it remains
unknown whether EVT is cost-effective in patients presenting with large ischemic core infarcts.
The implications of EVT on societal costs related to large stroke patients have also not been
studied in detail.

We sought to assess EVT cost-effectiveness by performing a cost- effectiveness analysis for
EVT as compared to medical management only (MM) using outcomes in patients with large
ischemic core infarcts on CT (ASPECTS <6), CTP (rCBF <30% volume ≥ 50 cm3) or both from
the SELECT study, a prospective, multicenter cohort study of imaging selection22.
This study sub-analysis aims were:
1. To assess the overall gain in QALYs
2. To identify the incremental cost-effectiveness ratio (ICER) for EVT
3. To assess the net monetary benefit (NMB) at various thresholds of willingness to pay
(WTP)
4. To compare EVT cost-effectiveness in patients with large ischemic core to those with
small core infarcts.
5. To assess EVT societal cost benefits in patients with large ischemic core

Methods:
Study population:
“The Optimizing Patient Selection for Endovascular Treatment in Acute Ischemic Stroke
(SELECT): a Prospective Multicenter Cohort Study of Imaging Selection”22 enrolled patients
with stroke attributable to large-vessel occlusion who were treated with endovascular
5

thrombectomy plus medical management or medical management alone, based on CT or CTP
findings, up to 24 hours from the point that they were last known to be well at 9 comprehensive
stroke centers across the United States. The decision to proceed with EVT vs medical
management alone was made at the discretion of the local investigators in a nonrandomized
fashion. The study initially included patients up to 8 hours after stroke onset, with the enrollment
window extended up to 24 hours after the results of the Clinical Mismatch in the Triage of Wake
Up and Late Presenting Strokes Undergoing Neurointervention With Trevo (DAWN) trial8 were
announced. Patients with large ischemic cores were defined as having an ASPECTS of 5 or less
on non-contrast CT or an ischemic core volume of 50 cm3 or more on CTP based on the volume
of tissue with a relative cerebral blood flow less than 30% at presentation.
Cost-Effectiveness Analysis:
We performed a cost-effectiveness analysis to compare costs and outcomes of endovascular
thrombectomy (EVT) in addition to medical management (MM) compared to MM only in
patients with large core acute ischemic stroke. The outcome measures were quality-adjusted life
years (QALYs). QALYs are assessed using the survival time and the utility associated to the
modified Rankin Scale (mRS) score. For each mRS score we used utility values obtained from a
recent consensus analysis. The analysis took the health care service provider perspective,
including only the costs of direct medical treatment (hospital admissions, ICU, rehabilitation).
An analysis from societal perspective was also attempted that accounts for the societal costs (as
in productivity losses, informal care and private cost for patients). Costs were calculated in 2017
US$, inflated where necessary23. The time horizon was selected to be over lifetime. All costs and
outcomes after the first year were discounted at an annual rate of 3%.
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Model Structure:
We created a decision analysis model to assess cost-effectiveness of EVT using TreeAge
Healthcare Pro version 2020 (TreeAge, Williamstown/MA). The treatment arms include best
MM (including the use of IV tPA where applicable) without subsequent EVT vs best MM
followed by EVT. The decision model consisted of two different models 1) a short run model to
assess the transitions measured at 90 days following stroke and 2) a long run model to assess
transitions over the course of lifetime following the initial stroke, beginning at 90-day post
stroke. The short run model analyzed the clinical outcomes and costs associated with the
treatment at 90-day interval following the index stroke. The long run model was created to
estimate the transitions in clinical outcomes and associated post-stroke costs with cycles of 1
year. At the end of each cycle, the patient could remain in the same health state, experience a
recurrent stroke and recover to the same state or transition to other states or die from stroke or
other causes. Outcomes were based on modified Rankin Scale (mRS) scores measured at 90 days
after stroke.24

Model Input Parameters
The initial probabilities for short run model to analyze 90 day clinical outcomes were identified
from the large core cohort of the SELECT study14. The study reported outcomes of 105 patients
(62 EVT, 43 MM) with large ischemic stroke on non-contrast CT, CT perfusion or both;
demonstrating functional independence rates of 31% and 14% in patients treated with EVT and
MM respectively. For comparative models for patients with small core, results provided in
HERMES metanalysis25 were used for short run models in early time window (0-6 hours),
DAWN8 and DEFUSE 39 results were used for trials beyond 6 hours of stroke onset. The
7

transitional probabilities beyond 90 days of stroke onset were populated using historical data
from multiple prospective cohort studies, identifying probabilities of recurrent stroke, death and
changes in functional status over the course of time for patients suffering from index stroke.26–28
The measures for utilities at different mRS categories were obtained from a prospectively
validated cohort evaluating EuroQol in post-stroke patients.29 Table 1 provides further
information regarding the parameters used in the decision analysis model.
Treatment Costs
Data was used from the National Inpatient Sample30 and data available in the literature31 to
estimate costs and we inflated as necessary using the inflation rate from national sources24. The
costs are presented in Table 1.
The additional cost of IV thrombolysis was estimated to be $6,961, including the cost of the
therapy, the medication and administration from the National Inpatient Sample30, inflated at the
2017 US $.
The cost of the EVT varied in each trial was estimated to be $14,454. This includes the cost of
the devices (stent-retreivers), materials and intervention.
The health care costs in the 3 months following a stroke include the acute management (length of
stay in the acute stroke unit, in the acute high dependency unit, and in the rehabilitation ward, as
well as the supported discharge cost and community care costs) and rehabilitation costs.32 The
ongoing costs in the following years include rehabilitation costs and follow-up costs.31 Both
acute and ongoing costs were applied based on the disability observed at 90-day on modified
Rankin Scale score in 7 different categories. The cost of a recurrent stroke was estimated as the
mean expected cost to treat an average stroke that does not need MM or EVT.33
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Initial and Transitional Probabilities
The initial probabilities were defined based on modified Rankin Scale score at 90 days and were
assessed using results from the SELECT study for patients presenting with large ischemic core
for the main results. The initial probabilities for comparison models with the trials were assessed
from the results published from the DAWN8 and DEFUSE 3 trials9 and HERMES metaanalysis25. The transitional probabilities were defined as the probability to move from one health
state to another after 90 days results and were implemented in annual cycle for the long run
model for a horizon of lifetime. The age specific annual death rates were obtained from United
States Life Tables.27 Excess deaths because of stroke were incorporated as additional hazard
ratios identified from the contemporary cohort studies.28 The other transitional probabilities were
also obtained from various large prospective cohorts.26
Cost-Utility Measures and Outcomes:
The cost-effectiveness of EVT was expressed in terms of its incremental cost-effectiveness ratio
(ICER), defined as the ratio of the difference in the costs between EVT and MM and gain in
Qality Adjusted Life Years between the treatments demonstrated by the model.

𝐼𝐶𝐸𝑅 =

𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝐸𝑉𝑇 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝑀𝑀
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝐴𝐿𝑌𝑠 𝑜𝑓 𝐸𝑉𝑇 − 𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝐴𝐿𝑌𝑠 𝑜𝑓 𝑀𝑀

Results are also expressed in terms of net monetary benefits (NMB), calculated as the mean
QALYs per patient accruing to that treatment multiplied by the willingness to pay (WTP) for a
QALY (the cost-effectiveness threshold) minus the mean cost per patient for the treatment.
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𝑁𝑒𝑡 𝑀𝑜𝑛𝑒𝑡𝑎𝑟𝑦 𝐵𝑒𝑛𝑒𝑓𝑖𝑡 = [𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑄𝐴𝐿𝑌𝑠 𝑤𝑖𝑡ℎ 𝐸𝑉𝑇 𝑋 𝑊𝑖𝑙𝑙𝑖𝑛𝑔𝑛𝑒𝑠𝑠 𝑡𝑜 𝑃𝑎𝑦] −
𝑀𝑒𝑎𝑛 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑖𝑛 𝑡ℎ𝑒 𝐶𝑜𝑠𝑡 𝑜𝑓 𝐸𝑉𝑇

The lower and upper willingness to pay for NMB calculations were set to $50,000 and $100,000
per QALY.
Analysis from Societal Perspective:
To assess the impact of index stroke on overall societal productivity, we used human captial
approach to calculate costs associated with lost productivity as well as costs of informal care
provided by the family. Lost societal productivity due to premature deaths and post stroke
morbidity were calculated separately. Using US Census Bureau34 gross wages and age-based
employment rates provided by US Bureau of Labor Statistics35, lost productivity due to
premature mortality was calculated. Furthermore, we assumed complete retirement at age 80.
Non-stroke related premature deaths were not considered for these evaluations.
To obtain the lost productivity due to stroke-related morbidity, the aforementioned productivity
measures were multiplied by relative earnings of stroke survivors (82.5%) and probabilities of
return to work (RTW) based on 90-day functional status. The cost of informal care provided by
the family members were stratified based on 90-day functional status and calculated using hourly
wages for home health aides for year 2017.34
Sensitivity Analysis
A probabilistic sensitivity analysis (PSA) was performed to establish the impact of the
uncertainty characterising the input parameters and assess the robustness of the results, using
10

10,000 runs for the second order Monte Carlo simulation. A distribution was assigned to each
parameter value and a random value from the corresponding distribution was selected to be used
as an input for the Markov model. The mean (median) cost, QALYs and NMB for each treatment
were calculated from the 10,000 simulations; and the probability that the interventions are costeffective is summarised in the cost-effectiveness acceptability curves (CEACs). We also
conducted the same analysis, using the data from randomized trials that proved EVT efficacy and
safety in patients with small ischemic core: HERMES25, DEFUSE 39 and DAWN8.

Results
Functional Outcomes in Patients with Large Ischemic Core Infarcts:
Of 361 patients enrolled in SELECT, 105 (29%) had a large ischemic core on CT or CTP or both
(EVT 62, MM 43). Functional independence (modified Rankin Scale score of 0-2) at 90 days
was achieved in 19 (31%) EVT patients vs 6 (14%) MM (OR: 3.27, 95% CI: 1.11-9.62; P = .03)
with a shift towards better mRS (cOR: 2.12, 95% CI: 1.05-4.31, P = .04)14. Mortality was
observed in 29% (18/62) of EVT and 42% (18/43) of MM patients, p=0.17. Neurological
worsening (EVT: 13/62 (21%) vs MM: 8/43 (20%), p=0.87) and symptomatic ICH (EVT: 8/62
(13%) vs 3/43 (7%), p=0.51).

Base Case Analysis:
Using base case values, EVT following MM performed in patients with large ischemic core
infarcts was associated with an incremental cost of $33,094 per patient over projected
lifetime(Table 2). EVT-treated patients could gain 1.34 incremental QALYs.
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The ICER of EVT compared to MM was $24,665 per QALY. The EVT has a higher NMB
compared to MM alone at the lower (EVT: -$42,747 vs MM: -$76,740) and upper (EVT:
$155,041 vs MM: $57,134) thresholds of WTP, indicating that EVT is cost-effective. EVT was
also associated with incremental costs of $28,962 in an analysis from the societal perspective.

Sensitivity Analysis:
Figure 2 demonstrates the probabilistic sensitivity analysis based on 10,000 simulations. A
significantly higher proportion of results are in the quadrant where an increment in costs is
associated with a QALY gain and most of the result are under the $100,000/QALY threshold
line, therefore there is a high probability that EVT is cost-effective. The cost-effectiveness
acceptability curves (CEAC) demonstrates the probability that each treatment is cost-effective at
different values of the willingness to pay for a QALY (Figure 3). EVT has 77% & 92%
probability of being cost-effective compared to MM when the willigness to pay is $50,000 and $
100,000 per QALY, respectively.

Comparison of EVT Cost-Effectiveness in Large Core Infarcts to Patients with Small Core
Infarcts:
Overall, data from HERMES meta-analysis in early time window and DAWN and DEFUSE 3 in
late time window demonstrated overall higher lifetime costs associated with MM as compared to
EVT. Cost-effectiveness analysis based on data from HERMES meta-analysis demonstrated
average overall cost savings of $29,964 over lifetime in patients treated with EVT, with a gain of
1.62 QALY (i.e. dominant over MM) and almost 100% probability of EVT being cost-effective
in probabilistic sensitivity analysis at lower and upper thresholds of WTP. EVT also decreased
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the societal costs by $38,072. Similar results are obtained based on outcomes from DAWN trial
(dominant) and DEFUSE 3 trial (dominant) with both the trials demonstrating almost 100% of
being cost-effective at the willingness to pay thresholds of $50,000 and $100,000. EVT was also
associated with a reduction in societal costs by $86,358 in DAWN and $22,837 in DEFUSE 3
trial. Table 3 demonstrates the comparison of incremental EVT costs, QALYs, ICER and societal
cost benefits in SELECT large ischemic core patients as compared to previously published RCTs
over the horizon of lifetime.

Discussion:
We found that EVT may result in more lives saved and improved quality of life in large core
patients from the SELECT prospective cohort study. This treatment strategy had an acceptable
ICER, a higher NMB and high probabilities of being cost-effective at even the lowest bounds of
current willingness-to-pay thresholds for the United States healthcare system.
Our analysis suggests that in patients with large ischemic core on CT or CTP, EVT was
associated with 1.34 QALY gained and ICER of $24,665 for each QALY gained. While it
resulted in initial $33,094 incremental cost per patient, EVT was associated with more lives
saved and improved likelihood of being functionally independent (mRS 0-2), increasing the
QALYs.

Our results showed an incremental lifetime cost associated with EVT as compared to prior RCTs
that enrolled patients with small core.8,9,25 This is to a large part likely due to the high mortality
rate in SELECT large core subpopulation that received MM only; 42% as compared to 19% in
HERMES25, in 26% in DEFUSE 39 and 18% in DAWN8. Such a high mortality rate
13

paradoxically largely reduces the cost in the MM group. For example, healthcare policy makers
recognize that life-saving interventions may increase long-term expenditures, creating counterintuitive results. Prominent examples include the effect of smoking cessation or of several
preventive measures, which may increase costs in the long run due to a higher life expectancy of
the population.36,37
Within the same lines, the social cost was higher in our large group cohort due to the reduced
mortality with EVT primarily with similar rates of severe and profound disability (mRS) 4-5
between EVT and MM as compared to a difference within the same mRS grades in prior EVT
RCTs. Additionally, the median age for our cohort was higher than prior RCTs which may have
resulted in an underestimation of the potential savings attributable to EVT and overall savings
including productivity losses and higher societal costs.
Previous studies demonstrated the cost-effectiveness of EVT compared to MM up to 24 hours of
stroke in small core infarcts15–21 with ICER significantly below the current willingness to pay
thresholds in patients included in randomized controlled trials (put references only from RCTs).
Since most of these trials excluded patients with large ischemic core, involvement of these
patients in such analyses is limited. Prior report18 demonstrated cost-effectiveness of EVT in
patients with ASPECTS of 0-5 at a higher ICER, however concluded that the estimates may be
uncertain because of systemic exclusion of such patients from the trials.
With several ongoing clinical trials assessing the efficacy and safety of EVT in stroke patients
with large ischemic core on different imaging modalities (SELECT 213, IN EXTREMIS12,
TESLA11, TENSION10), the randomized evidence is forthcoming in this important sub
population, which represents more than 20% of the patients encountered in daily practice.
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Meanwhile, our cost-effectiveness analysis from the SELECT prospective cohort14 suggests that
EVT may be cost-effective. These results, while still need to be confirmed based on data from
the upcoming RCTs, represent further evidence from economical, societal and quality of life
assessment to justify these randomized trials to evaluate intervening in patients with more
extensive areas of infarct.
There are limitations to our study that should be considered when interpreting the findings. This
includes the lack of randomization and potential selection biases associated with prospective,
cohort data. Additionally, we did not have direct economic data from the prospective cohort and
thus relied upon the overall payments based on current diagnosis-related group (DRG) for EVT.
Another limitation is represented by the variability in the methodology adopted in the different
trials of EVT effectiveness in patients with small core infarcts, including the use of different
devices and medical treatment to treat stroke. However, we conducted an extensive sensitivity
analysis that confirms the results.
The strengths of the presented study include data from a multicentre, prospective cohort study,
use of prior validated methods, inclusion of probabilistic sensitivity analysis and comparative
analysis with prior RCTs using the same parameters that allows for the direct comparison of
cost-effectiveness.
Conclusion:
EVT may result in better outcomes and more lives saved in large core patients with higher
QALYs, NMB and an acceptable ICER. This further justifies a randomized trial for EVT
efficacy and safety in patients with large core.
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Model Input
Initial probabilities for
achieving mRS 0/1/2/3/4/5/6
SELECT Large Core

Base-case value

Distribution

Source

Dirichlet

Sarraj et al.

Dirichlet

Goyal et al.

Dirichlet

Nogueira et al.

Dirichlet

Albers et al.

0.059 (for 1st y)

Beta

Pennlert et al.

0.013 (for 65 y)

Beta

Arias et al.

Log normal

Hong et al

Dirichlet

Goyal et al.

$7.996/$11.038/$17.336/$21.440/$28.729/$34,319/$8,067

Gamma

Dawson et al.

$6,961

Gamma

NIS 2014

$14,454

Gamma

Shireman et al.

$11,245/$11,579/$13,395/$23,009/ $46,553/$68,441

Gamma

Shireman et al.

$23,032

Gamma

Chambers et al.

Beta

Chaisinanunkul
et al.

Gamma

US Census
Bureau 2017

EVT

0.0806/0.0645/0.1613/0.0968/0.2419/0.0645/0.2903

MM Only

0.0233/0.0233/0.0930/0.1628/0.1628/0.1163/0.4186

HERMES
EVT

0.1000/0.1690/0.1910/0.1690/0.1560/0.0620/0.1530

MM Only

0.0500/0.0790/0.1360/0.1640/0.2470/0.1350/0.1890

DAWN
EVT

0.0900/0.2200/0.1700/0.1300/0.1300/0.0900/0.1600

MM Only

0.0400/0.0500/0.0400/0.1800/0.1600/0.1800/0.1800

DEFUSE 3
EVT

0.1000/0.1600/0.1800/0.1500/0.1800/0.0800/0.1400

MM Only

0.0800/0.0400/0.0400/0.1600/0.2700/0.1600/0.2600

Transition probabilities
Recurrent stroke rate
Annual death rate
Annual death hazard rates
for survivors mRS
0/1/2/3/4/5
After recurrent stroke
Health care costs
Costs within first 90 days
after stroke for mRS
0/1/2/3/4/5/6 (excluding IVT
and EVT)
Additional cost of IVT
treatment
Additional cost of EVT
treatment
Long-term annual costs
after stroke for mRS
0/1/2/3/4/5
Recurrent stroke
hospitalization

1.53/1.52/2.17/3.18/4.55/6.55
control arm from HERMES meta-analysis

Utilities
mRS 0/1/2/3/4/5/6

1.00/0.91/0.76/0.65/0.33/0.00/0.00

Societal costs
Paid workforce
productivity
Average annual earnings
of employed population

$33 000 (for 65 y)
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0.312 (for 65 y)

Beta

US Bureau of
Labor Statistics
2017

0.825

Beta

Vyas et al.

0.63/0.72/0.49/0.19/0.14/0.00

Beta

Tanaka et al.

Gamma

Hickenbottom
et al.

Population employment
rate
Relative earnings of stroke
survivors
Return-to-work after stroke
mRS 0/1/2/3/4/5
Unpaid domestic productivity
Informal annual caregiving
costs

mRS 0–1: $1503 mRS 2–5: $7518

Table 1 represents the model parameters and range of values used for sensitivity analysis. short
term transition probabilities were used from SELECT14, HERMES, DAWN8 and DEFUSE 39 population.
Long term transition probabilities were based on multiple large prospective cohort studies25, 27-29. Acute
costs in the first 3 months include baseline medical management including adminstration of IV tPA.
Utilities were derived from a validation cohort for EuroQol23.
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Endovascular
Thrombectomy

Medical Management

Difference

Cumulative Lifetime
$207,866
$ 240,959
$ 33,094
Costs
Cumulative Lifetime
3.96
2.62
1.34
QALYs gained
Incremental Cost per
$ 24,665
QALY gained
Table 2 demonstrates the Costs, QALYs, ICER and NMB of EVT versus Medical
treatment (MM) Based on results from patients with large core in SELECT trial. All costs
are calculated in 2017 US dollars.
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Incremental Costs
Incremental QALYs
ICER
Societal Costs

SELECT Large Core
$33,094
1.34
$24,665
$28,962

HERMES
-$29,964
1.62
Dominant
-$38,072

DAWN
-$69,887
2.36
Dominant
-$86,358

DEFUSE 3
-$12,723
2.21
Dominant
-$22,837

Table 3 describes the incremental costs, incremental QALY and ICERs of EVT versus MM
in USD in SELECT patients with large ischemic core over horizon of lifetime, as compared
to the previously published RCTs of patients with small core infarcts in both early and late
time window.
The high cost of EVT was in part owing to the high mortality in MM patients in SELECT
Large Core cohort, as compared to HERMES, DAWN and DEFUSE 3 cohorts. Similarly,
the social cost of EVT in SELECT large core cohort was due to the reduced mortality with
EVT primarily with similar rates of severe and profound disability (mRS) 4-5 between
EVT and MM as compared to a difference within the same mRS grades in prior EVT
RCTs.
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Figure 1. Decision model. A Short run analytical model is used to estimate costs within first
3 months of stroke. A long run Markov model is used to estimate transitions between states
and costs beyond first 3 months of stroke.
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Figure 2. Results of the Probabilistic Sensitivity Analysis (PSA). The figure demonstrates
10000 simulated iterations of the incremental cost per QALY gained of EVT in patients
with large core in the SELECT study (yellow), DAWN8 (green), DEFUSE39 (red) and
HERMES25 (blue). The results show that the higher proportion of results are in the quadrant
where an increment in costs is associated with a QALY gain and most of the result are under
the $50000/QALY threshold line, therefore there is a high probability that the EVT is costeffective. The long dashed line represents an ICER of $50,000/QALY gained and short dashed
line represents an ICER of $100,000/QALY gained. The high cost of EVT was in part owing
to the high mortality in MM patients in SELECT Large Core cohort, as compared to
HERMES, DAWN and DEFUSE 3 cohorts.
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Figure 3. Cost-Effectiveness Acceptability Curves (CEAC) of EVT versus MM in the data
from large core patients in SELECT trial14 (yellow), HERMES25 trial (blue), DAWN8 trial
(green)and DEFUSE 39 trial (red). The CEAC show the probability that each option is costeffective at different values of the willingness to pay for a QALY. Using SELECT data EVT has
77% probability of being cost-effective compared to MM when the willigness to pay is $50000
per QALY, and 92% probability of being cost-effective when the WTP is $100000 per QALY.
Conversly, MM has 23% and 8% probability of being cost-effective when the WTP is $50000
and $100000 per QALY respectively. EVT has a probability of being cost-effective of almost
100% in all other trials with a WTP of $50,000 and $100,000 per QALY. The high cost of EVT
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was in part owing to the high mortality in MM patients in SELECT Large Core cohort, as
compared to HERMES, DAWN and DEFUSE 3 cohorts.
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